What Is Skinny Labeling – And Will It Work for Biosimilars?

In this article, published in Biosimilar Development, Limin Zheng discusses the “skinny labeling” approach, which has been a successful strategy for generics to get around the brand’s follow-on “new use” patents. Given the differences between biosimilars and generics, whether the same approach will benefit biosimilar makers calls for a more complicated economic calculation.


Leave a Reply

Your email address will not be published. Required fields are marked *